Phibro Animal Health (NASDAQ:PAHC) CEO Jack Bendheim Sells 2,932 Shares

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 2,932 shares of Phibro Animal Health stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $40.02, for a total transaction of $117,338.64. Following the sale, the chief executive officer directly owned 44,525 shares in the company, valued at $1,781,890.50. This trade represents a 6.18% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Jack Bendheim also recently made the following trade(s):

• On Wednesday, January 14th, Jack Bendheim sold 3,651 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.53, for a total transaction of $147,975.03.
• On Tuesday, January 13th, Jack Bendheim sold 7,551 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.32, for a total value of $304,456.32.
• On Friday, January 9th, Jack Bendheim sold 213 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.16, for a total value of $8,554.08.
• On Wednesday, January 7th, Jack Bendheim sold 328 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.09, for a total value of $13,149.52.
• On Thursday, December 11th, Jack Bendheim sold 5,752 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.93, for a total value of $235,429.36.
• On Tuesday, December 9th, Jack Bendheim sold 1,288 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.19, for a total value of $51,764.72.
• On Monday, December 8th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.06, for a total value of $141,011.20.
• On Wednesday, December 3rd, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.77, for a total transaction of $143,510.40.
• On Tuesday, November 25th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $43.93, for a total transaction of $309,267.20.
• On Wednesday, November 26th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $44.02, for a total transaction of $232,425.60.

Phibro Animal Health Stock Up 0.5%

NASDAQ PAHC traded up $0.19 during trading hours on Thursday, reaching $40.06. 176,958 shares of the company traded hands, compared to its average volume of 194,706. The stock has a market capitalization of $1.62 billion, a PE ratio of 24.13, a PEG ratio of 1.14 and a beta of 0.79. The company has a current ratio of 3.09, a quick ratio of 1.35 and a debt-to-equity ratio of 2.32. Phibro Animal Health Corporation has a 12 month low of $16.16 and a 12 month high of $46.42. The company has a 50 day moving average of $40.70 and a two-hundred day moving average of $36.90.

Phibro Animal Health (NASDAQ:PAHC) last issued its earnings results on Wednesday, November 5th. The company reported $0.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.15. Phibro Animal Health had a net margin of 4.85% and a return on equity of 36.26%. The business had revenue of $363.89 million for the quarter, compared to analyst estimates of $345.44 million. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. As a group, equities analysts expect that Phibro Animal Health Corporation will post 1.95 earnings per share for the current year.

Phibro Animal Health Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, December 17th. Shareholders of record on Wednesday, November 26th were issued a dividend of $0.12 per share. This represents a $0.48 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend was Wednesday, November 26th. Phibro Animal Health’s dividend payout ratio (DPR) is currently 28.92%.

Institutional Investors Weigh In On Phibro Animal Health

Several hedge funds and other institutional investors have recently bought and sold shares of PAHC. Geode Capital Management LLC grew its stake in shares of Phibro Animal Health by 1.4% in the 2nd quarter. Geode Capital Management LLC now owns 554,927 shares of the company’s stock worth $14,175,000 after purchasing an additional 7,841 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Phibro Animal Health by 74.3% in the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock worth $7,733,000 after acquiring an additional 154,281 shares during the last quarter. Ranger Investment Management L.P. raised its position in shares of Phibro Animal Health by 101.1% during the second quarter. Ranger Investment Management L.P. now owns 357,970 shares of the company’s stock worth $9,143,000 after purchasing an additional 179,975 shares during the period. Invesco Ltd. lifted its holdings in shares of Phibro Animal Health by 22.5% during the third quarter. Invesco Ltd. now owns 322,299 shares of the company’s stock valued at $13,040,000 after purchasing an additional 59,226 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in shares of Phibro Animal Health by 9.6% during the third quarter. Arrowstreet Capital Limited Partnership now owns 301,605 shares of the company’s stock valued at $12,203,000 after purchasing an additional 26,539 shares during the last quarter. 99.34% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently issued reports on PAHC shares. JPMorgan Chase & Co. upped their price target on Phibro Animal Health from $45.00 to $50.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 29th. Finally, Zacks Research upgraded shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 9th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Phibro Animal Health presently has a consensus rating of “Hold” and a consensus price target of $31.40.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.